Clinical Handbook of Psychotropic Drugs 25th Edition

Clinical Handbook of Psychotropic Drugs
Author: by Ric M. Procyshyn (Editor), Kalyna Z. Bezchlibnyk-Butler (Editor), David D. Kim (Editor) & 0 more
Publisher: Hogrefe & Huber Pub
Edition: 25th
Publication Date: 2023-05-01
Language: English
Print Length: 480 pages
ISBN-10: 0889376328
ISBN-13: 9780889376328

Book Description

Quick and comprehensive information on psychotropic drugs for adults.

• – Accurate and up-to-date
• – Comparison charts help decision-making
• – Icons and full color
• – Available in print and online
• – Downloadable patient info sheets

The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists,physicians, pharmacists, nurses, and other mental health professionals.

• • Independent, unbiased, up-to-date
• • Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions…) for a quick overview of treatment options
• • Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more – all you need to know for each class of drug
• • Potential interactions and side effects summarized in comparison charts
• • With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
• • Clearly written patient information sheets available for download as printable PDF files

This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.

New in this edition:

• • Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion; Auvelity extended-release tablets)
• • Antipsychotics updates include revised Clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
• • Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised
• • Dementia chapter includes a new section on Lecanemab (Leqembi), a fast-track FDA approved treatment for Alzheimer’s disease
• • Treatment of Substance Use Disorders includes revisions to Buprenorphine dosing section to include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
• • Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetic chapters all substantially revised
• • New formulations and trade names include: Invega Hafyera (paliperidone long-acting 6-monthly IM injection), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)

Amazon page